Quick answers
- What is Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate (2) used for?
- The FDA-approved label (Adderall XR, Takeda Pharmaceuticals America, Inc., April 30, 2026) says: “ADDERALL XR, a CNS stimulant, is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older. Limitations of Use The use of ADDERALL XR is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the side effects of Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate (2)?
- The “Adverse Reactions” section of the FDA label (Adderall XR, Takeda Pharmaceuticals America, Inc., April 30, 2026) begins: “The following adverse reactions are discussed in greater detail in other sections of the labeling: Abuse, Misuse, and Addiction [see Boxed Warning, Warnings and Precautions (5.1), Drug Abuse and Dependence (9.2, 9.3)] Risks to Patients with Serious Cardiac Disease [see Warnings and Precautions (5.2)] Increased Blood Pressure and Heart Rate [see Warnings and Precautions (5.3)] Psychiatric Adverse Reactions [see Warnings and Precautions (5.4)] Long-Term Suppression of Growth …” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the drug interactions of Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate (2)?
- The “Drug Interactions” section of the FDA label (Adderall XR, Takeda Pharmaceuticals America, Inc., April 30, 2026) begins: “Alkalinizing agents (GI antacids and urinary): These agents increase blood levels of amphetamine. (2.7, 7.1) Acidifying agents (GI and urinary): These agents reduce blood levels of amphetamine. (7.1) 7.1 Clinically Important Interactions with Amphetamines Table 4: Drugs Having Clinically Important Interactions with Amphetamines Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate (2) have a boxed warning?
- Yes. The FDA label for Adderall XR has a boxed warning, the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
- Is there a shortage of Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate (2)?
- The FDA drug shortage list shows “Current shortage” for a product of this medicine (updated November 9, 2026). Ask your pharmacist about alternatives.
- Has Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate (2) been recalled?
- FDA enforcement reports list 17 recalls of products of this medicine; the newest started June 26, 2026 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate (2)?
- 24 companies list prescription products of Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate (2) in the FDA NDC Directory, including SpecGx LLC, Bryant Ranch Prepack and Teva Pharmaceuticals USA, Inc.
What Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate (2) is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
ADDERALL XR, a CNS stimulant, is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older. Limitations of Use The use of ADDERALL XR is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the …
— FDA label: Adderall XR, Takeda Pharmaceuticals America, Inc., effective April 30, 2026. Read the full label on DailyMed →
Label quoted: the one for the most common form (capsule, extended release, oral), Adderall XR, Takeda Pharmaceuticals America, Inc.; it covers 6 products in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.
The FDA has 47 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
This label has a boxed warning. Read it on the full label →
47 of 47 FDA labels for this medicine have a boxed warning.
Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate (2) boxed warning: what the label says
Quoted from the boxed warning of the FDA-approved label.
WARNING: ABUSE, MISUSE, and ADDICTION ADDERALL XR ® has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including ADDERALL XR, can result in overdose and death [see Overdosage (10)], and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.
Read more of this section
Before prescribing ADDERALL XR, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout ADDERALL XR treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Precautions (5.1), Drug Abuse and Dependence (9.2)]. WARNING: ABUSE, MISUSE, and ADDICTION See full prescribing information for complete boxed warning. ADDERALL XR has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including ADDERALL XR, can result in overdose and death (5.1, 9.2, 10): Before prescribing ADDERALL XR, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout treatment, reassess each patient’s risk and frequently monitor for signs and symptoms of abuse, misuse, and addiction.
— FDA label: Adderall XR, Takeda Pharmaceuticals America, Inc., effective April 30, 2026. Read the full label on DailyMed →
Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate (2) side effects
Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.
The following adverse reactions are discussed in greater detail in other sections of the labeling: Abuse, Misuse, and Addiction [see Boxed Warning, Warnings and Precautions (5.1), Drug Abuse and Dependence (9.2, 9.3)] Risks to Patients with Serious Cardiac Disease [see Warnings and Precautions (5.2)] Increased Blood Pressure and Heart Rate [see Warnings and Precautions (5.3)] Psychiatric Adverse Reactions [see Warnings and Precautions (5.4)] Long-Term Suppression of Growth …
Table from the label
| Body System | Preferred Term | ADDERALL XR (n=374) | Placebo (n=210) |
|---|---|---|---|
| General | Abdominal Pain (stomachache) Fever Infection Accidental Injury Asthenia (fatigue) | 14% 5% 4% 3% 2% | 10% 2% 2% 2% 0% |
| Digestive System | Loss of Appetite Vomiting Nausea Dyspepsia | 22% 7% 5% 2% | 2% 4% 3% 1% |
| Nervous System | Insomnia Emotional Lability Nervousness Dizziness | 17% 9% 6% 2% | 2% 2% 2% 0% |
| Metabolic/Nutritional | Weight Loss | 4% | 0% |
— FDA label: Adderall XR, Takeda Pharmaceuticals America, Inc., effective April 30, 2026. This is part of the section. Read the full label on DailyMed →
Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate (2) drug interactions
Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.
Alkalinizing agents (GI antacids and urinary): These agents increase blood levels of amphetamine. (2.7, 7.1) Acidifying agents (GI and urinary): These agents reduce blood levels of amphetamine. (7.1) 7.1 Clinically Important Interactions with Amphetamines Table 4: Drugs Having Clinically Important Interactions with Amphetamines Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis.
Read more of this section
Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Intervention Do not administer ADDERALL XR concomitantly or within 14 days after discontinuing MAOI [see Contraindications (4)]. Serotonergic Drugs Clinical Impact The concomitant use of ADDERALL XR and serotonergic drugs increases the risk of serotonin syndrome. Intervention Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during ADDERALL XR initiation or dosage increase. If serotonin syndrome occurs, discontinue ADDERALL XR and the concomitant serotonergic drug(s) [see Warnings and Precautions (5.8)]. CYP2D6 Inhibitors Clinical Impact The concomitant use of ADDERALL XR and CYP2D6 inhibitors may increase the exposure of ADDERALL XR compared to the use of the drug alone and increase the risk of serotonin syndrome. Intervention Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome particularly during ADDERALL XR initiation and after a dosage increase. If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor [see Warnings and Precautions (5.8), Overdosage (10)]. Alkalinizing Agents Clinical Impact Increase blood levels and potentiate the action of amphetamine. Intervention Coadministration of ADDERALL XR and gastrointestinal or urinary alkalinizing agents should be avoided. Acidifying Agents Clinical Impact Lower blood levels and efficacy of amphetamines. Intervention Increase dose based on clinical response. Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated. Intervention Monitor frequently and adjust or use alternative therapy based on clinical response. Proton Pump Inhibitors Clinical Impact Time to maximum concentration (T max) of amphetamine is decreased compared to when administered alone. Intervention Monitor patients for changes in clinical effect and adjust therapy based on clinical response. 7.2 Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. This increase is greatest in the evening. Amphetamines may interfere with urinary steroid determinations. Allow for an adequate washout period between administration of ADDERALL XR and radioactive diagnostic agents used for dopamine transporter (DAT) visualization.
— FDA label: Adderall XR, Takeda Pharmaceuticals America, Inc., effective April 30, 2026. This is part of the section. Read the full label on DailyMed →
Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate (2) dosage
Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.
Pediatric patients (ages 6 to 17): 10 mg once daily in the morning. Maximum dose for children 6 to 12 years of age is 30 mg once daily. (2.2, 2.3, 2.4) Adults: 20 mg once daily in the morning. (2.5) Pediatric patients (ages 6 to 17) with severe renal impairment: 5 mg once daily in the morning. Maximum dose for children 6 to 12 years of age with severe renal impairment is 20 mg once daily. (2.6, 8.6) Adults with severe renal impairment: 15 mg once daily in the morning.
Read more of this section
(2.6, 8.6) Patients with end stage renal disease (ESRD): Not recommended. (2.6, 8.6) 2.1 Pretreatment Screening Prior to treating patients with ADDERALL XR, assess: for the presence of cardiac disease (i.e., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam) [see Warnings and Precautions (5.2)]. the family history and clinically evaluate patients for motor or verbal tics or Tourette’s syndrome before initiating ADDERALL XR [see Warnings and Precautions (5.9)]. 2.2 General Administration Information Individualize the dosage according to the therapeutic needs and response of the patient. Administer ADDERALL XR at the lowest effective dosage. Based on bioequivalence data, patients taking divided doses of immediate-release ADDERALL, (for example, twice daily), may be switched to ADDERALL XR at the same total daily dose taken once daily. Titrate at weekly intervals to appropriate efficacy and tolerability as indicated. ADDERALL XR extended-release capsules may be taken whole, or the capsule may be opened and the entire contents sprinkled on applesauce. If the patient is using the sprinkle administration method, the sprinkled applesauce should be consumed immediately; it should not be stored. Patients should take the applesauce with sprinkled beads in its entirety without chewing. The dose of a single capsule should not be divided. The contents of the entire capsule should be taken, and patients should not take anything less than one capsule per day. ADDERALL XR may be taken orally with or without food. ADDERALL XR should be given upon awakening. Afternoon doses should be avoided because of the potential for insomnia. 2.3 Recommended Dosage in Pediatric Patients 6 to 12 Years In pediatric patients 6 to 12 years of age with ADHD and are either starting treatment for the first time or switching from another medication, start with 10 mg once daily in the morning; daily dosage may be adjusted in increments of 5 mg or 10 mg at weekly intervals. When in the judgment of the clinician a lower initial dose is appropriate, patients may begin treatment with 5 mg once daily in the morning. The maximum recommended dose for children 6 to 12 years of age is 30 mg/day; doses greater than 30 mg/day have not been studied in children. ADDERALL XR has not been studied in children under 6 years of age. 2.4 Recommended Dosage in Pediatric Patients 13 to 17 Years The recommended starting dose for pediatric patients 13 to 17 years of age with ADHD and are either starting treatment for the first time or switching from another medication is 10 mg/day.
— FDA label: Adderall XR, Takeda Pharmaceuticals America, Inc., effective April 30, 2026. This is part of the section. Read the full label on DailyMed →
Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate (2) in pregnancy
Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.
Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ADDERALL XR during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychostimulants at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/othermedications/.
Read more of this section
Risk Summary Available data from published epidemiologic studies and postmarketing reports on use of prescription amphetamine in pregnant women have not identified a drug-associated risk of major birth defects and miscarriage (see Data). Adverse pregnancy outcomes, including premature delivery and low birth weight, have been seen in infants born to mothers taking amphetamines during pregnancy (see Clinical Considerations). No apparent effects on morphological development were observed in embryo-fetal development studies, with oral administration of amphetamine to rats and rabbits during organogenesis at doses 2 and 12 times, respectively, the maximum recommended human dose (MRHD) of 20 mg/day given to adolescents, on a mg/m 2 basis. However, in a pre- and postnatal development study, amphetamine (d- to l- ratio of 3:1) administered orally to pregnant rats during gestation and lactation caused a decrease in pup survival and a decrease in pup body weight that correlated with a delay in developmental landmarks at clinically relevant doses of amphetamine. In addition, adverse effects on reproductive performance were observed in pups whose mothers were treated with amphetamine. Long-term neurochemical and behavioral effects have also been reported in animal developmental studies using clinically relevant doses of amphetamine (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions Amphetamines, such as ADDERALL XR, cause vasoconstriction and thereby may decrease placental perfusion. In addition, amphetamines can stimulate uterine contractions, increasing the risk of premature delivery. Infants born to mothers taking amphetamines during pregnancy have an increased risk of premature delivery and low birth weight. Monitor infants born to mothers taking amphetamines for symptoms of withdrawal such as feeding difficulties, irritability, agitation, and excessive drowsiness. Data Animal Data Amphetamine (d- to l- enantiomer ratio of 3:1) had no apparent effects on embryofetal morphological development or survival when administered orally to pregnant rats and rabbits throughout the period of organogenesis at doses of up to 6 and 16 mg/kg/day, respectively. These doses are approximately 2 and 12 times, respectively, the maximum recommended human dose (MRHD) of 20 mg/day given to adolescents, on a mg/m 2 basis.
— FDA label: Adderall XR, Takeda Pharmaceuticals America, Inc., effective April 30, 2026. This is part of the section. Read the full label on DailyMed →
When Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate (2) should not be used
Quoted from the “Contraindications” section of the FDA-approved label.
ADDERALL XR administration is contraindicated in patients: known to be hypersensitive to amphetamine, or other components of ADDERALL XR.
Read more of this section
Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions (6.2)]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see Warnings and Precautions (5.8), Drug Interactions (7.1)]. Known hypersensitivity or idiosyncrasy to amphetamine. (4) During or within 14 days following the administration of monoamine oxidase inhibitors (MAOI). (4, 7.1)
— FDA label: Adderall XR, Takeda Pharmaceuticals America, Inc., effective April 30, 2026. Read the full label on DailyMed →
Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate (2) overdose
Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).
Clinical Effects of Overdose Overdose of CNS stimulants is characterized by the following sympathomimetic effects: Cardiovascular effects including tachyarrhythmias, and hypertension or hypotension. Vasospasm, myocardial infarction, or aortic dissection may precipitate sudden cardiac death. Takotsubo cardiomyopathy may develop. CNS effects including psychomotor agitation, confusion, and hallucinations.
Read more of this section
Serotonin syndrome, seizures, cerebral vascular accidents, and coma may occur. Life-threatening hyperthermia (temperatures greater than 104°F) and rhabdomyolysis may develop. Overdose Management Consider the possibility of multiple drug ingestion. The pharmacokinetic profile of ADDERALL XR should be considered when treating patients with overdose. D-amphetamine is not dialyzable. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.
— FDA label: Adderall XR, Takeda Pharmaceuticals America, Inc., effective April 30, 2026. Read the full label on DailyMed →
Forms and how it is given
| Dosage forms | Capsule, extended release · Tablet · Capsule |
|---|---|
| Route | Oral |
| Prescription products | 203 in the FDA NDC Directory |
| Brand names | Adderall, Adderall XR, Mixed Salts of a Single Entity Amphetamine Product XR, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Tablets,cii, Mixed Salts of a Single-Entity Amphetamine Product, Mydayis |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| amphetamine aspartate monohydrate 1.25 mg · amphetamine sulfate 1.25 mg · dextroamphetamine saccharate 1.25 mg · dextroamphetamine sulfate 1.25 mg capsule | Generic | $0.5122 per capsule |
| amphetamine aspartate monohydrate 1.25 mg · amphetamine sulfate 1.25 mg · dextroamphetamine saccharate 1.25 mg · dextroamphetamine sulfate 1.25 mg capsule, extended release | Generic | $0.5122 per capsule |
| amphetamine aspartate monohydrate 1.25 mg · amphetamine sulfate 1.25 mg · dextroamphetamine saccharate 1.25 mg · dextroamphetamine sulfate 1.25 mg capsule, extended release | Brand: Adderall XR | $6.83 per capsule |
| amphetamine aspartate monohydrate 1.25 mg · amphetamine sulfate 1.25 mg · dextroamphetamine saccharate 1.25 mg · dextroamphetamine sulfate 1.25 mg tablet | Generic | $0.2494 per tablet |
| amphetamine aspartate monohydrate 1.25 mg · amphetamine sulfate 1.25 mg · dextroamphetamine saccharate 1.25 mg · dextroamphetamine sulfate 1.25 mg tablet | Brand: Adderall | $12.20 per tablet |
| amphetamine aspartate monohydrate 1.875 mg · amphetamine sulfate 1.875 mg · dextroamphetamine saccharate 1.875 mg · dextroamphetamine sulfate 1.875 mg tablet | Generic | $0.2906 per tablet |
| amphetamine aspartate monohydrate 12.5 mg · amphetamine sulfate 12.5 mg · dextroamphetamine saccharate 12.5 mg · dextroamphetamine sulfate 12.5 mg capsule, extended release | Generic | $8.27 per capsule |
| amphetamine aspartate monohydrate 12.5 mg · amphetamine sulfate 12.5 mg · dextroamphetamine saccharate 12.5 mg · dextroamphetamine sulfate 12.5 mg capsule, extended release | Brand: Mydayis | $10.77 per capsule |
| amphetamine aspartate monohydrate 2.5 mg · amphetamine sulfate 2.5 mg · dextroamphetamine saccharate 2.5 mg · dextroamphetamine sulfate 2.5 mg capsule | Generic | $0.5467 per capsule |
| amphetamine aspartate monohydrate 2.5 mg · amphetamine sulfate 2.5 mg · dextroamphetamine saccharate 2.5 mg · dextroamphetamine sulfate 2.5 mg capsule, extended release | Generic | $0.5467 per capsule |
| amphetamine aspartate monohydrate 2.5 mg · amphetamine sulfate 2.5 mg · dextroamphetamine saccharate 2.5 mg · dextroamphetamine sulfate 2.5 mg capsule, extended release | Brand: Adderall XR | $6.81 per capsule |
| amphetamine aspartate monohydrate 2.5 mg · amphetamine sulfate 2.5 mg · dextroamphetamine saccharate 2.5 mg · dextroamphetamine sulfate 2.5 mg tablet | Generic | $0.2271 per tablet |
| amphetamine aspartate monohydrate 2.5 mg · amphetamine sulfate 2.5 mg · dextroamphetamine saccharate 2.5 mg · dextroamphetamine sulfate 2.5 mg tablet | Brand: Adderall | $12.20 per tablet |
| amphetamine aspartate monohydrate 3.125 mg · amphetamine sulfate 3.125 mg · dextroamphetamine saccharate 3.125 mg · dextroamphetamine sulfate 3.125 mg capsule, extended release | Generic | $8.59 per capsule |
| amphetamine aspartate monohydrate 3.125 mg · amphetamine sulfate 3.125 mg · dextroamphetamine saccharate 3.125 mg · dextroamphetamine sulfate 3.125 mg capsule, extended release | Brand: Mydayis | $10.76 per capsule |
| amphetamine aspartate monohydrate 3.125 mg · amphetamine sulfate 3.125 mg · dextroamphetamine saccharate 3.125 mg · dextroamphetamine sulfate 3.125 mg tablet | Generic | $0.3509 per tablet |
| amphetamine aspartate monohydrate 3.75 mg · amphetamine sulfate 3.75 mg · dextroamphetamine saccharate 3.75 mg · dextroamphetamine sulfate 3.75 mg capsule | Generic | $0.5710 per capsule |
| amphetamine aspartate monohydrate 3.75 mg · amphetamine sulfate 3.75 mg · dextroamphetamine saccharate 3.75 mg · dextroamphetamine sulfate 3.75 mg capsule, extended release | Generic | $0.5710 per capsule |
| amphetamine aspartate monohydrate 3.75 mg · amphetamine sulfate 3.75 mg · dextroamphetamine saccharate 3.75 mg · dextroamphetamine sulfate 3.75 mg capsule, extended release | Brand: Adderall XR | $6.81 per capsule |
| amphetamine aspartate monohydrate 3.75 mg · amphetamine sulfate 3.75 mg · dextroamphetamine saccharate 3.75 mg · dextroamphetamine sulfate 3.75 mg tablet | Generic | $0.2311 per tablet |
| amphetamine aspartate monohydrate 3.75 mg · amphetamine sulfate 3.75 mg · dextroamphetamine saccharate 3.75 mg · dextroamphetamine sulfate 3.75 mg tablet | Brand: Adderall | $12.13 per tablet |
| amphetamine aspartate monohydrate 5 mg · amphetamine sulfate 5 mg · dextroamphetamine saccharate 5 mg · dextroamphetamine sulfate 5 mg capsule | Generic | $0.6243 per capsule |
| amphetamine aspartate monohydrate 5 mg · amphetamine sulfate 5 mg · dextroamphetamine saccharate 5 mg · dextroamphetamine sulfate 5 mg capsule, extended release | Generic | $0.6243 per capsule |
| amphetamine aspartate monohydrate 5 mg · amphetamine sulfate 5 mg · dextroamphetamine saccharate 5 mg · dextroamphetamine sulfate 5 mg capsule, extended release | Brand: Adderall XR | $6.80 per capsule |
| amphetamine aspartate monohydrate 5 mg · amphetamine sulfate 5 mg · dextroamphetamine saccharate 5 mg · dextroamphetamine sulfate 5 mg tablet | Generic | $0.2857 per tablet |
| amphetamine aspartate monohydrate 5 mg · amphetamine sulfate 5 mg · dextroamphetamine saccharate 5 mg · dextroamphetamine sulfate 5 mg tablet | Brand: Adderall | $12.20 per tablet |
| amphetamine aspartate monohydrate 6.25 mg · amphetamine sulfate 6.25 mg · dextroamphetamine saccharate 6.25 mg · dextroamphetamine sulfate 6.25 mg capsule | Generic | $0.5625 per capsule |
| amphetamine aspartate monohydrate 6.25 mg · amphetamine sulfate 6.25 mg · dextroamphetamine saccharate 6.25 mg · dextroamphetamine sulfate 6.25 mg capsule, extended release | Generic | $0.5625–$7.91 per capsule 12 packages, lowest to highest |
| amphetamine aspartate monohydrate 6.25 mg · amphetamine sulfate 6.25 mg · dextroamphetamine saccharate 6.25 mg · dextroamphetamine sulfate 6.25 mg capsule, extended release | Brand: Adderall XR | $6.80 per capsule |
| amphetamine aspartate monohydrate 6.25 mg · amphetamine sulfate 6.25 mg · dextroamphetamine saccharate 6.25 mg · dextroamphetamine sulfate 6.25 mg capsule, extended release | Brand: Mydayis | $10.79 per capsule |
| amphetamine aspartate monohydrate 7.5 mg · amphetamine sulfate 7.5 mg · dextroamphetamine saccharate 7.5 mg · dextroamphetamine sulfate 7.5 mg capsule | Generic | $0.4759 per capsule |
| amphetamine aspartate monohydrate 7.5 mg · amphetamine sulfate 7.5 mg · dextroamphetamine saccharate 7.5 mg · dextroamphetamine sulfate 7.5 mg capsule, extended release | Generic | $0.4759 per capsule |
| amphetamine aspartate monohydrate 7.5 mg · amphetamine sulfate 7.5 mg · dextroamphetamine saccharate 7.5 mg · dextroamphetamine sulfate 7.5 mg capsule, extended release | Brand: Adderall XR | $6.81 per capsule |
| amphetamine aspartate monohydrate 7.5 mg · amphetamine sulfate 7.5 mg · dextroamphetamine saccharate 7.5 mg · dextroamphetamine sulfate 7.5 mg tablet | Generic | $0.2900 per tablet |
| amphetamine aspartate monohydrate 7.5 mg · amphetamine sulfate 7.5 mg · dextroamphetamine saccharate 7.5 mg · dextroamphetamine sulfate 7.5 mg tablet | Brand: Adderall | $12.25 per tablet |
| amphetamine aspartate monohydrate 9.375 mg · amphetamine sulfate 9.375 mg · dextroamphetamine saccharate 9.375 mg · dextroamphetamine sulfate 9.375 mg capsule, extended release | Generic | $8.65 per capsule |
| amphetamine aspartate monohydrate 9.375 mg · amphetamine sulfate 9.375 mg · dextroamphetamine saccharate 9.375 mg · dextroamphetamine sulfate 9.375 mg capsule, extended release | Brand: Mydayis | $10.75 per capsule |
NADAC list of November 11, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- SpecGx LLC16 products
- Bryant Ranch Prepack15 products
- Teva Pharmaceuticals USA, Inc.14 products
- Camber Pharmaceuticals, Inc.13 products
- Granules Pharmaceuticals Inc.13 products
- Rhodes Pharmaceuticals LLC13 products
- Elite Laboratories, Inc.13 products
- Sandoz Inc10 products
- Takeda Pharmaceuticals America, Inc.10 products
- Lannett Company, LLC7 products
- Aurolife Pharma, LLC7 products
- Sunrise Pharmaceutical, Inc.7 products
- Oryza Pharmaceuticals Inc.6 products
- Amneal Pharmaceuticals of New York LLC6 products
- Burel Pharmaceuticals, LLC6 products
- Golden State Medical Supply, Inc.6 products
- Lannett Company, Inc.6 products
- Actavis Pharma, Inc.6 products
- Prasco Laboratories6 products
- Epic Pharma, LLC5 products
- NorthStar RxLLC5 products
- Alvogen Inc.5 products
- Sun Pharmaceutical Industries, Inc.4 products
- Teva Pharmaceuticals, Inc.4 products
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA021303 ADDERALL XR 10, ADDERALL XR 15, ADDERALL XR 20, ADDERALL XR 25, ADDERALL XR 30, ADDERALL XR 5 | Takeda Pharms USA | October 11, 2001 | 24, latest April 23, 2026 2026: Labeling · 2025: Labeling · 2023: Labeling |
| NDA022063 MYDAYIS | Takeda Pharms USA | June 20, 2017 | 4, latest April 23, 2026 2026: Labeling · 2023: Labeling · 2022: Labeling |
Generic approvals (25)
- ANDA040422Barr · February 11, 2002
- ANDA040439Sandoz · June 14, 2002
- ANDA040444Epic Pharma LLC · June 19, 2002
- ANDA040440Specgx LLC · October 7, 2003
- ANDA077302Actavis Elizabeth · June 22, 2012
- ANDA202424Aurolife Pharma LLC · November 27, 2013
- ANDA076852Impax Labs · February 16, 2016
- ANDA207388Alvogen · July 28, 2017
- ANDA209799Nuvo Pharm · December 28, 2017
- ANDA211352Elite Labs Inc · December 7, 2018
- ANDA205401Ani Pharms · January 22, 2019
- ANDA211547Specgx LLC · April 22, 2019
- ANDA210651Rhodes Pharms · May 17, 2019
- ANDA212037Elite Labs Inc · December 11, 2019
- ANDA210293Pharmobedient · April 3, 2020
- ANDA213111Rhodes Pharms · January 13, 2021
- ANDA213709Ascent Pharms Inc · April 22, 2021
- ANDA214959Ascent Pharms Inc · September 29, 2021
- ANDA214403Lannett Co Inc · November 26, 2021
- ANDA215771Granules · December 28, 2021
- ANDA210876Teva Pharms USA · January 31, 2022
- ANDA215565Lannett Co Inc · July 8, 2022
- ANDA217027Granules · January 23, 2023
- ANDA211546Specgx LLC · August 31, 2023
- ANDA215997Sun Pharm Inds Inc · September 27, 2023
Shortage status
Current shortage · updated November 9, 2026 · first posted October 12, 2022
| Product | Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0185-0853-0 |
|---|---|
| Availability | Limited Availability |
| Reason given | Other |
| Company | Sandoz Inc. |
Ask your pharmacist whether your product is affected and what the options are.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
June 26, 2026 · Class II · Ongoing · D-0660-2026
Labeling: Label Mix-up: Capsules contain only immediate-release (IR) pellets while labeled as ER capsules.
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate Extended-Release Capsules, 5 mg, Rx Only, 100 capsules, Distributed by: Lannett Company, Inc., Philadelph — Lannett Company Inc.
-
August 28, 2025 · Class III · Ongoing · D-0671-2025
Failed Impurities/Degradation Specifications:
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate, Extended-Release Capsules, (Mixed Salts of a Single Entity Amphetamine Product), 15 mg, 100 Capsules, Rx — Granules Pharmaceuticals Inc.
-
August 28, 2025 · Class III · Ongoing · D-0673-2025
Failed Impurities/Degradation Specifications:
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate, Extended-Release Capsules, (Mixed Salts of a Single Entity Amphetamine Product), 30 mg, 100 Capsules, Rx — Granules Pharmaceuticals Inc.
-
August 28, 2025 · Class III · Ongoing · D-0672-2025
Failed Impurities/Degradation Specifications:
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate, Extended-Release Capsules, (Mixed Salts of a Single Entity Amphetamine Product), 20 mg, 100 Capsules, Rx — Granules Pharmaceuticals Inc.
-
August 28, 2025 · Class III · Ongoing · D-0670-2025
Failed Impurities/Degradation Specifications:
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate, Extended-Release Capsules, (Mixed Salts of a Single Entity Amphetamine Product), 10 mg, 100 Capsules, Rx — Granules Pharmaceuticals Inc.
-
August 28, 2025 · Class III · Ongoing · D-0669-2025
Failed Impurities/Degradation Specifications:
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate, Extended-Release Capsules, (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 100 Capsules, Rx — Granules Pharmaceuticals Inc.
-
August 19, 2025 · Class II · Completed · D-0642-2025
Presence of Foreign Tablet/Capsule: Two (2) bottles labeled as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, 10mg, 100ct, contained one (1) tablet of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate T
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, 10mg, 100 Tablets per bottle, Rx only, Distributed by: Lannett Company, Inc., Philadelphia, PA 19136, NDC 05 — Lannett Company Inc.
-
August 29, 2022 · Class II · Terminated · D-1539-2022
Labeling: Label Error on Declared Strength; A sealed 100-count bottle labeled with 15 mg actually contained 100 tablets of 20 mg strength of the drug product.
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 15 mg, Rx Only, 100 tablets per bottle, Teva Pharmaceut — Teva Pharmaceuticals USA Inc
-
May 22, 2020 · Class II · Terminated · D-1285-2020
Some bottles may contain mixed strengths of the product.
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets ( Mixed Amphetamine Salts Product), 5 mg, 100 count bottles, Rx Only, Teva Pharmaceuticals USA, INC. North Wa — Teva Pharmaceuticals USA
-
May 22, 2020 · Class II · Terminated · D-1287-2020
Some bottles may contain mixed strengths of the product.
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets ( Mixed Amphetamine Salts Product), 20 mg, 100 count bottles, Rx Only, Teva Pharmaceuticals USA, INC. North W — Teva Pharmaceuticals USA
-
May 22, 2020 · Class II · Terminated · D-1286-2020
Some bottles may contain mixed strengths of the product.
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets ( Mixed Amphetamine Salts Product), 15 mg, 100 count bottles, Rx Only, Teva Pharmaceuticals USA, INC. North W — Teva Pharmaceuticals USA
-
September 19, 2019 · Class II · Terminated · D-0143-2020
Superpotent Drug: Amphetamine Mixed Salts 20mg have been found to be out of specification for weight and thickness.
Dextroamphetamine Sacharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Mixed Salts of a single Entity Amphetamine Product), 20mg, 100-count bottle, RX Only, Distributed by: Aurobin — Aurobindo Pharma USA Inc.
-
November 12, 2015 · Class II · Terminated · D-0566-2016
Failed Impurities/Degradation Specifications: High out of specification test result for impurities during stability testing.
DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE Tablets (Mixed Salts of a Single Entity Amphetamine Product), 10 mg, 100-count bottle, Rx only, Teva Pharmaceuticals — Teva Pharmaceuticals USA
-
June 24, 2015 · Class II · Terminated · D-1283-2015
Failed Impurities/Degradation Specifications: out of specification for unknown impurity
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, (CII), 10 mg (Mixed Salts of a Single Entity Amphetamine Product), 100 count bottles, manufactured at Barr L — Teva Pharmaceuticals USA
-
October 8, 2014 · Class II · Terminated · D-0050-2015
Failed Impurities/Degradation Specifications: Out of specification for unknown impurities.
DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE Tablets, (CII), 10 mg, 100 Tablet Bottles, Rx Only. Teva Pharmaceuticals USA , Sellersville, PA 18960, NDC: 0555-0972 — Teva Pharmaceuticals USA
-
January 24, 2014 · Class II · Terminated · D-1094-2014
CGMP Deviations: Dextroamphetamine Saccharate, Amphetamine Asparate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, CII, 10 mg were manufactured using unapproved material: the finished product was not properly quarantined as rejected due to inadequate cleaning of equipment.
Teva Dextroamphetamine Saccharate, Amphetamine Asparate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, CII, 10 mg (mixed salts) , 100 count-bottle, Rx Only, Distributed by Teva Pharmaceuticals, USA, Sellersv — Teva Pharmaceuticals USA
-
February 13, 2013 · Class III · Terminated · D-190-2013
Failed Dissolution Specification: This product recall is due to the product lot # 50077231 exceeding dissolution specifications. All other test specifications were met.
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended-Release Capsules, 15 mg, Rx Only, C II, 100 capsules per bottle, MFG. By Actavis Elizabeth LLC. 200 — Actavis Elizabeth LLC
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
| RxCUI (RxNorm) | 541363, 541365, 541878, 541879, 541892, 541894, 577957, 577960, 577961, 577962 … (+10) |
|---|---|
| SPL set ID of the quoted label | aff45863-ffe1-4d4f-8acf-c7081512a6c0 |
| FDA labels (SPL) | 47 |
| FDA applications | NDA021303, NDA022063, 25 ANDA |
| Active ingredients (FDA) | AMPHETAMINE ASPARTATE MONOHYDRATE / AMPHETAMINE SULFATE / DEXTROAMPHETAMINE SACCHARATE / DEXTROAMPHETAMINE SULFATE |
Next steps
- Find a pharmacy near youAsk which price applies to you and whether your product is affected by a recall
- Latest FDA drug recallsAll medicines, newest first
- AdderallBrand page: products, maker and price
- Adderall XRBrand page: products, maker and price
- MydayisBrand page: products, maker and price
- ADHDCondition named on the label: hospitals that treat it
- SpecGx LLCMaker or distributor
- Bryant Ranch PrepackMaker or distributor
- Teva Pharmaceuticals USA, Inc.Maker or distributor
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Adderall XR, Takeda Pharmaceuticals America, Inc., effective April 30, 2026; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →